Peripheral T-cell lymphoma: Difference between revisions
From WikiMD's Wellness Encyclopedia
No edit summary Tag: visualeditor-wikitext |
CSV import |
||
| (3 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
{{Infobox medical condition | |||
| name = Peripheral T-cell lymphoma | |||
| synonyms = PTCL | |||
| field = [[Hematology]] | |||
| symptoms = [[Lymphadenopathy]], [[fever]], [[weight loss]], [[night sweats]] | |||
| complications = [[Infection]], [[organ failure]] | |||
| onset = Typically in [[adulthood]] | |||
| duration = Chronic | |||
| types = [[Angioimmunoblastic T-cell lymphoma]], [[Anaplastic large cell lymphoma]], [[Extranodal NK/T-cell lymphoma]] | |||
| causes = Unknown, potential [[genetic]] and [[environmental]] factors | |||
| risks = [[Age]], [[gender]], [[ethnicity]], [[family history]] | |||
| diagnosis = [[Biopsy]], [[immunophenotyping]], [[imaging studies]] | |||
| differential = [[B-cell lymphoma]], [[Hodgkin lymphoma]], [[reactive lymphoid hyperplasia]] | |||
| prevention = None known | |||
| treatment = [[Chemotherapy]], [[radiation therapy]], [[stem cell transplant]] | |||
| prognosis = Variable, generally poor | |||
| frequency = Rare | |||
}} | |||
(peh-RIH-feh-rul ... lim-FOH-muh) One of a group of aggressive (fast-growing) non-Hodgkin lymphomas that begin in mature T lymphocytes (T cells that have matured in the thymus gland and gone to other lymphatic sites in the body, including lymph nodes, bone marrow, and spleen). Also called mature T-cell lymphoma. | (peh-RIH-feh-rul ... lim-FOH-muh) One of a group of aggressive (fast-growing) non-Hodgkin lymphomas that begin in mature T lymphocytes (T cells that have matured in the thymus gland and gone to other lymphatic sites in the body, including lymph nodes, bone marrow, and spleen). Also called mature T-cell lymphoma. | ||
'''Peripheral T-cell lymphoma''' refers to a group of [[T-cell lymphoma]]s that develop away from the [[thymus]]. | '''Peripheral T-cell lymphoma''' refers to a group of [[T-cell lymphoma]]s that develop away from the [[thymus]]. | ||
Examples include: | Examples include: | ||
* [[Cutaneous T-cell lymphomas]] | * [[Cutaneous T-cell lymphomas]] | ||
| Line 11: | Line 28: | ||
* [[Anaplastic large cell lymphoma]] | * [[Anaplastic large cell lymphoma]] | ||
* [[Peripheral T-cell lymphoma-Not-Otherwise-Specified]] | * [[Peripheral T-cell lymphoma-Not-Otherwise-Specified]] | ||
Treatment | Treatment | ||
The medication(s) listed below have been approved by the Food and Drug Administration (FDA) as orphan products for treatment of this condition. | The medication(s) listed below have been approved by the Food and Drug Administration (FDA) as orphan products for treatment of this condition. | ||
| Line 17: | Line 33: | ||
* '''[[Belinostat]] '''(Brand name: Beleodaq)belinostat (Beleodaq) was approved for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma(PTCL). | * '''[[Belinostat]] '''(Brand name: Beleodaq)belinostat (Beleodaq) was approved for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma(PTCL). | ||
* '''[[Pralatrexate]]''' (Brand name: Folotyn)pralatrexate (Folotyn) was approved for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma. | * '''[[Pralatrexate]]''' (Brand name: Folotyn)pralatrexate (Folotyn) was approved for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma. | ||
{{Lymphoid malignancy}} | {{Lymphoid malignancy}} | ||
[[Category:Non-Hodgkin lymphoma]] | [[Category:Non-Hodgkin lymphoma]] | ||
{{rarediseases}} | {{rarediseases}} | ||
{{stub}} | {{stub}} | ||
{{No image}} | |||
Latest revision as of 01:55, 4 April 2025
| Peripheral T-cell lymphoma | |
|---|---|
| Synonyms | PTCL |
| Pronounce | N/A |
| Specialty | N/A |
| Symptoms | Lymphadenopathy, fever, weight loss, night sweats |
| Complications | Infection, organ failure |
| Onset | Typically in adulthood |
| Duration | Chronic |
| Types | Angioimmunoblastic T-cell lymphoma, Anaplastic large cell lymphoma, Extranodal NK/T-cell lymphoma |
| Causes | Unknown, potential genetic and environmental factors |
| Risks | Age, gender, ethnicity, family history |
| Diagnosis | Biopsy, immunophenotyping, imaging studies |
| Differential diagnosis | B-cell lymphoma, Hodgkin lymphoma, reactive lymphoid hyperplasia |
| Prevention | None known |
| Treatment | Chemotherapy, radiation therapy, stem cell transplant |
| Medication | N/A |
| Prognosis | Variable, generally poor |
| Frequency | Rare |
| Deaths | N/A |
(peh-RIH-feh-rul ... lim-FOH-muh) One of a group of aggressive (fast-growing) non-Hodgkin lymphomas that begin in mature T lymphocytes (T cells that have matured in the thymus gland and gone to other lymphatic sites in the body, including lymph nodes, bone marrow, and spleen). Also called mature T-cell lymphoma.
Peripheral T-cell lymphoma refers to a group of T-cell lymphomas that develop away from the thymus.
Examples include:
- Cutaneous T-cell lymphomas
- Angioimmunoblastic T-cell lymphoma
- Extranodal natural killer/T-cell lymphoma, nasal type
- Enteropathy type T-cell lymphoma
- Subcutaneous panniculitis-like T-cell lymphoma
- Anaplastic large cell lymphoma
- Peripheral T-cell lymphoma-Not-Otherwise-Specified
Treatment The medication(s) listed below have been approved by the Food and Drug Administration (FDA) as orphan products for treatment of this condition.
- Brentuximub vedotin (Brand name: Adcetris) brentuximab vedotin (Adcetris) was approved for the treatment of adult patients with previously untreated systemic anaplastic large cell lymphoma (sALCL) or other CD30-expressing peripheral T-cell lymphomas (PTCL), including angioimmunoblastic T-cell lymphoma and PTCL not otherwise specified, in combination with cyclophosphamide, doxorubicin, and prednisone. In November 2016, it was approved for treatment of adult patients with primary cutaneous anaplastic large cell lymphoma. In August 2011, it was approved for the treatment of patients with systemic anaplastic large cell lymphoma (sALCL) after failure of at least one prior multi-agent chemotherapy regimen.
- Belinostat (Brand name: Beleodaq)belinostat (Beleodaq) was approved for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma(PTCL).
- Pralatrexate (Brand name: Folotyn)pralatrexate (Folotyn) was approved for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma.
| Leukaemias, lymphomas and related disease | ||||
|---|---|---|---|---|
|
NIH genetic and rare disease info[edit]
Peripheral T-cell lymphoma is a rare disease.
| Rare and genetic diseases | ||||||
|---|---|---|---|---|---|---|
|
Rare diseases - Peripheral T-cell lymphoma
|
